NMDP℠ Organizes Nationwide Fundraisers to Propel Research, Aid Patients with Blood Cancer and Diseases
13 sept. 2024 09h00 HE
|
NMDP
NMDP, a global leader in cell therapy, will host its first-ever community event series, NMDP: Unite to help find cures for blood cancers and diseases.
2024 Research Report | Hematology Analyzers and Reagents Market Anticipated to Reach USD 8.8 Billion by 2029
05 sept. 2024 11h22 HE
|
Research and Markets
Dublin, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The "Hematology Analyzers and Reagents Market Size, Share & Trends by Product (Instrument (PoC, Semi-automated), Reagent, Consumable, Service), Price...
Vor Bio to Participate in Upcoming Investor Conferences
28 août 2024 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
NMDP℠ Raises More Than $235,000 at Annual LA Gala Fundraiser
13 août 2024 10h00 HE
|
NMDP
NMDP recently hosted its annual gala in Los Angeles to raise critical funds that support patient financial assistance and innovation in cell therapy.
Bionano Announces Presentation of Optical Genome Mapping Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2024 Annual Meeting
01 août 2024 08h00 HE
|
Bionano Genomics
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- A sponsored exhibitor session will feature Dr. Phillip Michaels from Harvard Medical School and Brigham and Women’s Hospital presenting data from a...
Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma
23 juil. 2024 08h00 HE
|
Bionano Genomics
SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome...
Scientific Presentations Highlight OGM’s Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
02 juil. 2024 08h00 HE
|
Bionano Laboratories
At a sponsored workshop, Su Yang from The University of Texas MD Anderson Cancer Center will present case studies that demonstrate the ability of the optical genome mapping (OGM) workflow to detect...
ExCellThera Announces EMA’s Acceptance under Accelerated Assessment of Market Authorisation Application (MAA) for UM171 Cell Therapy for Patients with Hematological Malignancies who Lack a Readily Available Suitable Donor
25 juin 2024 07h00 HE
|
ExCellThera
Market Authorisation Application (MAA) for ExCellThera's UM171 Cell Therapy accepted under accelerated assessment by the European Medicines Agency
Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
17 juin 2024 16h05 HE
|
Bionano Laboratories
American Medical Association issues Category I CPT code for the use of optical genome mapping in genome-wide analysis related to hematological malignancies
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
09 mai 2024 16h05 HE
|
Vor Biopharma
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...